Literature DB >> 25624017

Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors.

Masayuki Imamura1, Yuji Nakamoto2, Suguru Uose3, Izumi Komoto1,4, Masaaki Awane4, Yoshiro Taki4.   

Abstract

Functioning pancreaticoduodenal neuroendocrine tumors (PD-NETs) are popular in a textbook, but they are still unfamiliar to a general clinician, and delay of diagnosis or misdiagnosis has been reported even today. It is a consensus that sporadic functioning PD-NET is cured only by surgical resection. So, early detection and early resection is the gold standard for the treatment of functioning PD-NET. Functioning PD-NETs in patients with multiple endocrine neoplasia type 1 (MEN 1) are often multiple. You should check about MEN 1 whenever you encountered multiple PD-NET. They are diagnosed in younger age than sporadic cases. In most cases they are accompanied with numerous microscopic or macroscopic nonfunctioning P-NETs, which are potentially metastatic and the most common cause of death in MEN 1 patients.
© 2015 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Functioning duodenal neuroendocrine tumor; Functioning pancreaticoduodenal neuroendocrine tumor; Gastrinoma; Insulinoma

Mesh:

Year:  2015        PMID: 25624017     DOI: 10.1002/jhbp.209

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  5 in total

1.  Clinical treatment of gastrinoma: A case report and review of the literature.

Authors:  Wei-Dong Zhang; DA-Ren Liu; Pei Wang; Jian-Gang Zhao; Zhe-Fang Wang; L I Chen
Journal:  Oncol Lett       Date:  2016-03-31       Impact factor: 2.967

2.  Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy.

Authors:  Aya Maekawa; Atsushi Kudo; Mitsuhiro Kishino; Yoshiki Murase; Shuichi Watanabe; Yoshiya Ishikawa; Hiroki Ueda; Keiichi Akahoshi; Kosuke Ogawa; Hiroaki Ono; Shinji Tanaka; Yuko Kinowaki; Minoru Tanabe
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-27       Impact factor: 4.553

3.  Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report.

Authors:  Maridi Aerts; Hendrik Reynaert
Journal:  Case Rep Gastroenterol       Date:  2017-12-06

4.  Insulinoma with a History of Epilepsy: Still a Possible Misleading Factor in the Early Diagnosis of Insulinoma.

Authors:  Takaaki Murakami; Takafumi Yamashita; Daisuke Yabe; Toshihiko Masui; Yuki Teramoto; Sachiko Minamiguchi; Keisho Hirota; Masahito Ogura; Kazuaki Nagashima; Nobuya Inagaki
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

5.  JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.

Authors:  Tetsuhide Ito; Toshihiko Masui; Izumi Komoto; Ryuichiro Doi; Robert Y Osamura; Akihiro Sakurai; Masafumi Ikeda; Koji Takano; Hisato Igarashi; Akira Shimatsu; Kazuhiko Nakamura; Yuji Nakamoto; Susumu Hijioka; Koji Morita; Yuichi Ishikawa; Nobuyuki Ohike; Atsuko Kasajima; Ryoji Kushima; Motohiro Kojima; Hironobu Sasano; Satoshi Hirano; Nobumasa Mizuno; Taku Aoki; Takeshi Aoki; Takao Ohtsuka; Tomoyuki Okumura; Yasutoshi Kimura; Atsushi Kudo; Tsuyoshi Konishi; Ippei Matsumoto; Noritoshi Kobayashi; Nao Fujimori; Yoshitaka Honma; Chigusa Morizane; Shinya Uchino; Kiyomi Horiuchi; Masanori Yamasaki; Jun Matsubayashi; Yuichi Sato; Masau Sekiguchi; Shinichi Abe; Takuji Okusaka; Mitsuhiro Kida; Wataru Kimura; Masao Tanaka; Yoshiyuki Majima; Robert T Jensen; Koichi Hirata; Masayuki Imamura; Shinji Uemoto
Journal:  J Gastroenterol       Date:  2021-09-29       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.